The headline on the CMS proposed rule published this week will be about Ozempic and the big cardiometabolic drugs. The more durable story, for anyone tracking the economics of psychiatric pharmaceuticals, is quieter and already underway: Medicare drug-price negotiation has reached the category, and this rule is what makes that reach permanent.
What the rule does
The proposed rule, issued by the Centers for Medicare and Medicaid Services on June 16, would codify the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, moving it from temporary guidance into permanent regulation, and would govern the selection of up to 20 high-expenditure drugs per year beginning with the price-applicability year 2029. Comments are due in mid-August. The program negotiates what the statute calls maximum fair prices for high-expenditure, single-source Part D and Part B drugs. The negotiated prices for the first 10 selected drugs took effect on January 1, 2026, a second set of 15 takes effect in 2027, and the program has now secured prices on 25 drugs in total.
Codification is the substantive move. The rule transitions the program from annually updated guidance to a durable regulatory framework, codifies the formulary-inclusion requirements and the definition of a negotiated price, adds protections for small biotech companies, and tightens the rules that determine when a new formulation counts as a distinct drug, a provision aimed at curbing the lifecycle-extension tactics manufacturers have used to delay negotiation. Combined with the statutory limits on administrative and judicial review of selection and pricing decisions, and the manufacturers’ so-far-unsuccessful court challenges, codification raises the probability that the program survives future legal and administrative attempts to unwind it. For pricing models, that means negotiation should be treated as a structural feature, not a contingency.
Psychiatry is already in the regime
The reason this matters for a behavioral-health audience is not speculative. The second negotiation round, with prices effective in 2027, already includes psychiatric and psychiatric-adjacent drugs.
Vraylar, AbbVie’s atypical antipsychotic for bipolar I disorder, schizophrenia, and adjunctive major depression, was selected with roughly $1.09 billion in gross Medicare spending across about 116,000 enrollees. Its negotiated price is $770 a month, a 44 percent reduction from the $1,376 list price. Austedo and Austedo XR, Teva’s deuterated treatment for tardive dyskinesia, frequently a consequence of antipsychotic use, and Huntington’s chorea, were also selected, with a negotiated price of $4,093 down from $6,623 and roughly $1.5 billion in Medicare spend. Antipsychotics sit in a protected class under Part D, meaning plans must cover them, and although generics account for the large majority of utilization, the expensive branded products account for most of the gross spending in the class, which is precisely what makes them negotiation targets.
Where it goes next
From 2029 the program scales to as many as 20 drugs a year, and as it scales, more high-spend branded psychiatric drugs become candidates. Analysts already flag Rexulti, the brexpiprazole product used for adjunctive depression, schizophrenia, and agitation in Alzheimer’s, as a likely selection for the 2028 cycle. The selection logic favors single-source drugs with high gross Medicare spending and seven or more years on the market without generic or biosimilar competition, which describes a recognizable set of branded central-nervous-system drugs. For manufacturers of those drugs, the question has shifted from whether negotiation applies to when in the lifecycle the price cut lands.
The caveat that keeps this honest
Two qualifications matter. First, this week’s rule names no new drugs. The future CNS impact depends on selection cycles that are not guaranteed for any specific product, so the durable claim is about the framework, not about which antidepressant or antipsychotic is next. Second, the headline percentage cuts are measured against list price, not net price. Manufacturers already pay substantial rebates on branded drugs, so a 44 percent cut from Vraylar’s list price is not a 44 percent cut to AbbVie’s realized revenue, and the true revenue impact depends on the gap between the negotiated maximum fair price and the manufacturer’s current net price after rebates. Headlines that treat the list-price reduction as the revenue hit overstate it.
The frame
For this publication’s audience the takeaway is structural. Psychiatric pharma has crossed into the Medicare negotiation regime, Vraylar is the marker, and the June 16 rule ensures the regime is permanent and expanding rather than a temporary IRA experiment that might be reversed. For any branded central-nervous-system drug with a large Medicare book and a long market tenure, negotiation is now a feature of the lifecycle to plan around, not a risk to hope past. The branded antidepressants, antipsychotics, and addiction treatments with significant Part D spend are no longer outside this story. They are in the queue.